Share on StockTwits

Uroplasty (NYSE:UPI) CEO Robert Kill bought 13,950 shares of the company’s stock in a transaction that occurred on Monday, June 2nd. The shares were purchased at an average cost of $2.95 per share, with a total value of $41,152.50. Following the completion of the transaction, the chief executive officer now directly owns 500,000 shares of the company’s stock, valued at approximately $1,475,000. The purchase was disclosed in a legal filing with the SEC, which is available at this link.

Uroplasty (NYSE:UPI) traded down 3.75% during mid-day trading on Wednesday, hitting $2.82. 104,504 shares of the company’s stock traded hands. Uroplasty has a one year low of $1.69 and a one year high of $5.40. The stock has a 50-day moving average of $3.16 and a 200-day moving average of $3.47. The company’s market cap is $60.3 million.

Uroplasty (NYSE:UPI) last posted its quarterly earnings results on Thursday, May 15th. The company reported ($0.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.04) by $0.01. During the same quarter in the previous year, the company posted ($0.05) earnings per share. On average, analysts predict that Uroplasty will post $-0.20 earnings per share for the current fiscal year.

Uroplasty, Inc is a medical device company that develops, manufactures and markets products for the treatment of voiding dysfunctions.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.